ARF-BP1/Mule is a critical mediator of the ARF tumor suppressor

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• The ARF tumor suppressor's role in p53 regulation is known, but its p53/Mdm2-independent growth suppression mechanisms require elucidation.
• Understanding ARF's tumor suppression pathways is crucial for developing targeted cancer therapies.

Purpose of the Study:

• To investigate the molecular mechanisms underlying ARF-mediated tumor suppression.
• To identify key factors interacting with ARF in vivo and elucidate their roles in cell growth regulation.

Main Methods:

• Identification of ARF-interacting proteins using co-immunoprecipitation and in vivo association studies.
• Assessment of ubiquitin ligase activity of ARF-BP1 and its inhibition by ARF.
• Analysis of cell growth in p53-null and p53 wild-type cells following ARF-BP1 inactivation.
• Investigation of ARF-BP1's direct interaction with and ubiquitination of p53.

Main Results:

• ARF-BP1, a HECT-motif containing ubiquitin ligase, was identified as an ARF-interacting protein.
• ARF inhibits ARF-BP1's ubiquitin ligase activity.
• ARF-BP1 inactivation suppressed p53-null cell growth, mimicking ARF induction.
• ARF-BP1 directly ubiquitinates p53, and its inactivation is essential for ARF-mediated p53 stabilization in p53 wild-type cells.

Conclusions:

• ARF-BP1 is a critical mediator of both p53-dependent and p53-independent tumor suppressor functions of ARF.
• ARF-BP1's dual role suggests it as a potential therapeutic target for various cancers, irrespective of p53 status.